HBOC 201 (Hemopure)

02/01/2000 - "These data indicate that HBOC-201 improved early survival and stabilized hemodynamic and metabolic parameters vs. lactated Ringer's in this swine model of liver injury with uncontrolled, lethal hemorrhage that simulates the prehospital care environment where allogenic blood is unavailable."
11/01/2005 - "HBOC-201 has only been used for management of acute hemorrhage, and its utility in providing longer term transfusion support is unknown. "
10/01/2004 - "Despite evidence of vasoactivity, HBOC-201 more effectively stabilized tissue oxygenation, reversed anaerobic metabolism, decreased bleeding, and increased survival in comparison with HEX. "
11/01/2003 - "We have shown in a previous work that HBOC-201 is able to reverse anaerobic metabolism at low volumes in a porcine model of controlled hemorrhage. "
03/01/2008 - "Swine underwent brain impact injury and hemorrhage to a mean arterial pressure (MAP) of 40 mm Hg. Twenty swine were randomized to undergo resuscitation with HBOC-201 (6 ml/kg) or LR solution (12 ml/kg) and were observed for an average of 6.5 +/- 0.5 hours following resuscitation. "

02/01/2014 - "Hypertonic HBOC-201 decreases neutrophil activation after hemorrhagic shock."
01/01/2007 - "Innate immune responses in Swine resuscitated from severe traumatic hemorrhagic shock with hemoglobin-based oxygen carrier-201."
09/01/2005 - "As HBOC-201 restored hemodynamics and tissue oxygenation and decreased fluid requirements, in comparison with HEX, HBOC-201 was at least as efficacious and possibly a superior resuscitative fluid in a military-relevant delayed evacuation hemorrhagic shock swine model."
10/01/2004 - "As HBOC-201 improves outcome in animals with hemorrhagic shock (HS), we compared HBOC-201 and HEX (used by U.S. "
07/01/2002 - "HBOC-201 improves survival in a swine model of hemorrhagic shock and liver injury."

01/01/2005 - "The study was performed in order to assess the potential of low dose HBOC-201 to improve tumor oxygenation. "
11/01/2005 - "HBOC-201 alone did not effect tumor or muscle tpO(2). "
01/01/2005 - "HBOC-201 alone failed to improve tumor tpO2 (b: 1.3 +/- 1.2mmHg; 15min: 1.4 +/- 1 mmHg; 60min: 1 +/- 1 mmHg). "
11/01/2005 - "TCD50% values of 119 Gy (95% confidence interval 103;135), 111 Gy (84;138), and 102 Gy (83;120) were determined for tumors irradiated alone, in combination with HBOC-201, and with HBOC-201 plus carbogen, respectively. "
11/01/2005 - "In addition, the effect of HBOC-201 alone or in combination with carbogen on the tpO(2) of tumor and muscle was determined using a flexible stationary probe (Licox, GMS). "

03/01/2010 - "Time from onset of anemia (< or = 8 g/dL) to HBOC-201 infusion was shorter for survivors than nonsurvivors (3.2 vs 4.4 days, P = 0.027). "
06/01/2007 - "Hemopure transfusion in a child with severe anemia."
07/01/2010 - "Hemopure may represent a life-saving intervention in patients with severe symptomatic anemia when blood transfusion is not an option."
07/01/2002 - "HBOC-201 may be an initial alternative to red blood cell transfusions for patients with moderate anemia after cardiac surgery. "
03/01/2010 - "Earlier, compared with later, administration by inexperienced users of HBOC-201 to patients with anemia was associated with improved chances of survival of acutely bleeding and hemolyzing patients. "

01/01/2007 - "We conclude that in swine with severe controlled HS and soft tissue injury, immune responses are similar with resuscitation with HBOC-201 and Hextend."
09/01/2005 - "To evaluate the efficacy of HBOC-201 for resuscitation of hemorrhagic shock in a swine model incorporating soft tissue injury and delayed evacuation. "
01/01/2006 - "Anesthetized pigs underwent soft tissue injury, controlled hemorrhage of 40% of blood volume, and resuscitation with HBOC-201 or Hextend, or no resuscitation. "
01/01/2007 - "Herein, we evaluated HBOC-201's immune effects in swine with more severe hemorrhagic shock due to soft tissue injury and 55% blood volume catheter withdrawal over 15 minutes followed by fluid resuscitation at 20 minutes with HBOC-201, Hextend, or no treatment (NON) before hospital arrival. "